Alex R. Thurman Sells 442 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 442 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $105.69, for a total transaction of $46,714.98. Following the sale, the chief financial officer now owns 52,090 shares of the company’s stock, valued at approximately $5,505,392.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Glaukos Trading Up 2.8 %

Shares of GKOS opened at $107.93 on Wednesday. The stock has a market capitalization of $5.42 billion, a P/E ratio of -37.48 and a beta of 1.08. The company has a current ratio of 5.38, a quick ratio of 4.68 and a debt-to-equity ratio of 0.78. The business’s 50-day moving average price is $93.94 and its 200 day moving average price is $83.62. Glaukos Co. has a 1-year low of $54.38 and a 1-year high of $110.73.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. The firm had revenue of $85.60 million during the quarter, compared to analyst estimates of $79.60 million. During the same quarter in the previous year, the firm posted ($0.59) earnings per share. Glaukos’s quarterly revenue was up 15.8% compared to the same quarter last year. Analysts expect that Glaukos Co. will post -2.2 earnings per share for the current year.

Analyst Ratings Changes

GKOS has been the subject of a number of recent research reports. StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Tuesday, February 27th. Stifel Nicolaus reiterated a “buy” rating and set a $110.00 price target on shares of Glaukos in a research report on Wednesday, April 3rd. BTIG Research boosted their price objective on Glaukos from $107.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. JPMorgan Chase & Co. increased their target price on Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Finally, Needham & Company LLC boosted their price target on shares of Glaukos from $108.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $108.64.

Institutional Investors Weigh In On Glaukos

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC boosted its stake in Glaukos by 20.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 5,582 shares of the medical instruments supplier’s stock valued at $420,000 after purchasing an additional 959 shares during the period. Xponance Inc. acquired a new position in shares of Glaukos during the third quarter worth approximately $208,000. Raymond James & Associates boosted its position in shares of Glaukos by 18.9% in the third quarter. Raymond James & Associates now owns 12,898 shares of the medical instruments supplier’s stock valued at $971,000 after acquiring an additional 2,053 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Glaukos by 10.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,916 shares of the medical instruments supplier’s stock worth $746,000 after acquiring an additional 898 shares during the last quarter. Finally, Mackenzie Financial Corp bought a new position in Glaukos during the third quarter worth $203,000. 99.04% of the stock is owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.